{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:06:19Z","timestamp":1792789579578,"version":"4.5.0"},"reference-count":39,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T00:00:00Z","timestamp":1692921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III (ISCIII) and FEDER","doi-asserted-by":"publisher","award":["PI20\/00969"],"award-info":[{"award-number":["PI20\/00969"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III (ISCIII) and FEDER","doi-asserted-by":"publisher","award":["CB16\/12\/00328"],"award-info":[{"award-number":["CB16\/12\/00328"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III (ISCIII) and FEDER","doi-asserted-by":"publisher","award":["GCTRA1804MATI Grupos Coordinados Clinicos AECC 2018"],"award-info":[{"award-number":["GCTRA1804MATI Grupos Coordinados Clinicos AECC 2018"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III (ISCIII) and FEDER","doi-asserted-by":"publisher","award":["IN606A-2022\/018"],"award-info":[{"award-number":["IN606A-2022\/018"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014139","name":"CIBERONC","doi-asserted-by":"publisher","award":["PI20\/00969"],"award-info":[{"award-number":["PI20\/00969"]}],"id":[{"id":"10.13039\/501100014139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014139","name":"CIBERONC","doi-asserted-by":"publisher","award":["CB16\/12\/00328"],"award-info":[{"award-number":["CB16\/12\/00328"]}],"id":[{"id":"10.13039\/501100014139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014139","name":"CIBERONC","doi-asserted-by":"publisher","award":["GCTRA1804MATI Grupos Coordinados Clinicos AECC 2018"],"award-info":[{"award-number":["GCTRA1804MATI Grupos Coordinados Clinicos AECC 2018"]}],"id":[{"id":"10.13039\/501100014139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014139","name":"CIBERONC","doi-asserted-by":"publisher","award":["IN606A-2022\/018"],"award-info":[{"award-number":["IN606A-2022\/018"]}],"id":[{"id":"10.13039\/501100014139","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AECC","award":["PI20\/00969"],"award-info":[{"award-number":["PI20\/00969"]}]},{"name":"AECC","award":["CB16\/12\/00328"],"award-info":[{"award-number":["CB16\/12\/00328"]}]},{"name":"AECC","award":["GCTRA1804MATI Grupos Coordinados Clinicos AECC 2018"],"award-info":[{"award-number":["GCTRA1804MATI Grupos Coordinados Clinicos AECC 2018"]}]},{"name":"AECC","award":["IN606A-2022\/018"],"award-info":[{"award-number":["IN606A-2022\/018"]}]},{"DOI":"10.13039\/501100010769","name":"Axencia Galega de Innovacion","doi-asserted-by":"publisher","award":["PI20\/00969"],"award-info":[{"award-number":["PI20\/00969"]}],"id":[{"id":"10.13039\/501100010769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010769","name":"Axencia Galega de Innovacion","doi-asserted-by":"publisher","award":["CB16\/12\/00328"],"award-info":[{"award-number":["CB16\/12\/00328"]}],"id":[{"id":"10.13039\/501100010769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010769","name":"Axencia Galega de Innovacion","doi-asserted-by":"publisher","award":["GCTRA1804MATI Grupos Coordinados Clinicos AECC 2018"],"award-info":[{"award-number":["GCTRA1804MATI Grupos Coordinados Clinicos AECC 2018"]}],"id":[{"id":"10.13039\/501100010769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010769","name":"Axencia Galega de Innovacion","doi-asserted-by":"publisher","award":["IN606A-2022\/018"],"award-info":[{"award-number":["IN606A-2022\/018"]}],"id":[{"id":"10.13039\/501100010769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Gynaecological serous carcinomas (GSCs) constitute a distinctive entity among female tumours characterised by a very poor prognosis. In addition to late-stage diagnosis and a high rate of recurrent disease associated with massive peritoneal carcinomatosis, the systematic acquisition of resistance to first-line chemotherapy based on platinum determines the unfavourable outcome of GSC patients. To explore the molecular mechanisms associated with platinum resistance, we generated patient-derived organoids (PDOs) from liquid biopsies of GSC patients. PDOs are emerging as a relevant preclinical model system to assist in clinical decision making, mainly from tumoural tissue and particularly for personalised therapeutic options. To approach platinum resistance in a GSC context, proficient PDOs were generated from the ascitic fluid of ovarian, primary peritoneal and uterine serous carcinoma patients in platinum-sensitive and platinum-resistant clinical settings from the uterine aspirate of a uterine serous carcinoma patient, and we also induced platinum resistance in vitro in a representative platinum-sensitive PDO. Histological and immunofluorescent characterisation of these ascites-derived organoids showed resemblance to the corresponding original tumours, and assessment of platinum sensitivity in these preclinical models replicated the clinical setting of the corresponding GSC patients. Differential gene expression profiling of a panel of 770 genes representing major canonical cancer pathways, comparing platinum-sensitive and platinum-resistant PDOs, revealed cellular response to DNA damage stimulus as the principal biological process associated with the acquisition of resistance to the first-line therapy for GSC. Additionally, candidate genes involved in regulation of cell adhesion, cell cycles, and transcription emerged from this proof-of-concept study. In conclusion, we describe the generation of PDOs from liquid biopsies in the context of gynaecological serous carcinomas to explore the molecular determinants of platinum resistance.<\/jats:p>","DOI":"10.3390\/ijms241713208","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T08:25:33Z","timestamp":1692951933000},"page":"13208","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Ascites-Derived Organoids to Depict Platinum Resistance in Gynaecological Serous Carcinomas"],"prefix":"10.3390","volume":"24","author":[{"given":"Andrea Estrella","family":"Arias-Diaz","sequence":"first","affiliation":[{"name":"Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s\/n, 15706 Santiago de Compostela, Spain"},{"name":"Department of Medicine, Universidade de Santiago de Compostela (USC), 15782 Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Ferreiro-Pantin","sequence":"additional","affiliation":[{"name":"Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s\/n, 15706 Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Barbazan","sequence":"additional","affiliation":[{"name":"Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s\/n, 15706 Santiago de Compostela, Spain"},{"name":"Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Monforte de Lemos 3-5, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edurne","family":"Perez-Beliz","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s\/n, 15706 Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Ruiz-Ba\u00f1obre","sequence":"additional","affiliation":[{"name":"Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s\/n, 15706 Santiago de Compostela, Spain"},{"name":"Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Monforte de Lemos 3-5, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Casas-Arozamena","sequence":"additional","affiliation":[{"name":"Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s\/n, 15706 Santiago de Compostela, Spain"},{"name":"Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Monforte de Lemos 3-5, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Muinelo-Romay","sequence":"additional","affiliation":[{"name":"Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s\/n, 15706 Santiago de Compostela, Spain"},{"name":"Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Monforte de Lemos 3-5, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Lopez-Lopez","sequence":"additional","affiliation":[{"name":"Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s\/n, 15706 Santiago de Compostela, Spain"},{"name":"Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Monforte de Lemos 3-5, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Vilar","sequence":"additional","affiliation":[{"name":"Department of Gynecology, University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s\/n, 15706 Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Curiel","sequence":"additional","affiliation":[{"name":"Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s\/n, 15706 Santiago de Compostela, Spain"},{"name":"Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Monforte de Lemos 3-5, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3533-7781","authenticated-orcid":false,"given":"Miguel","family":"Abal","sequence":"additional","affiliation":[{"name":"Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s\/n, 15706 Santiago de Compostela, Spain"},{"name":"Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Monforte de Lemos 3-5, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrclinonc.2015.224","article-title":"Can Advanced-Stage Ovarian Cancer Be Cured?","volume":"13","author":"Narod","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/ijgo.13878","article-title":"Cancer of the Ovary, Fallopian Tube, and Peritoneum: 2021 Update","volume":"155","author":"Berek","year":"2021","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","article-title":"Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer","volume":"385","author":"Harter","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"6395","DOI":"10.1038\/s41388-021-02055-2","article-title":"A Highly Annotated Database of Genes Associated with Platinum Resistance in Cancer","volume":"40","author":"Huang","year":"2021","journal-title":"Oncogene"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","article-title":"Ovarian Cancer Development and Metastasis","volume":"177","author":"Lengyel","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrc3432","article-title":"Meeting the Challenge of Ascites in Ovarian Cancer: New Avenues for Therapy and Research","volume":"13","author":"Kipps","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13046-021-01917-7","article-title":"Patient-Derived Organoids and High Grade Serous Ovarian Cancer: From Disease Modeling to Personalized Medicine","volume":"40","author":"Nero","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_8","first-page":"e64878","article-title":"Generation and Culturing of High-Grade Serous Ovarian Cancer Patient-Derived Organoids","volume":"191","author":"Graham","year":"2023","journal-title":"J. Vis. Exp."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.stemcr.2020.03.004","article-title":"Developing Organoids from Ovarian Cancer as Experimental and Preclinical Models","volume":"14","author":"Maenhoudt","year":"2020","journal-title":"Stem Cell Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/s41556-019-0360-z","article-title":"Patient-Derived Organoids from Endometrial Disease Capture Clinical Heterogeneity and Are Amenable to Drug Screening","volume":"21","author":"Boretto","year":"2019","journal-title":"Nat. Cell Biol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Nakamura, M., Obata, T., Daikoku, T., and Fujiwara, H. (2019). The Association and Significance of P53 in Gynecologic Cancers: The Potential of Targeted Therapy. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20215482"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.anndiagpath.2013.04.011","article-title":"Coordinate Patterns of Estrogen Receptor, Progesterone Receptor, and Wilms Tumor 1 Expression in the Histopathologic Distinction of Ovarian from Endometrial Serous Adenocarcinomas","volume":"17","author":"Fadare","year":"2013","journal-title":"Ann. Diagn. Pathol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/dc.21426","article-title":"Pax8: A Marker for Carcinoma of M\u00fcllerian Origin in Serous Effusions","volume":"39","author":"Tong","year":"2011","journal-title":"Diagn. Cytopathol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Giordano, G., Ferioli, E., and Tafuni, A. (2022). The Role of Mesothelin Expression in Serous Ovarian Carcinoma: Impacts on Diagnosis, Prognosis, and Therapeutic Targets. Cancers, 14.","DOI":"10.20944\/preprints202201.0271.v1"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"112890","DOI":"10.1016\/j.envres.2022.112890","article-title":"A Multi-Tissue Study of Immune Gene Expression Profiling Highlights the Key Role of the Nasal Epithelium in COVID-19 Severity","volume":"210","year":"2022","journal-title":"Environ. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2217\/fon.12.112","article-title":"The Changing Landscape of Therapeutic Strategies for Recurrent Ovarian Cancer","volume":"8","author":"Baumann","year":"2012","journal-title":"Future Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.canlet.2011.03.018","article-title":"Molecular Portraits of Intratumoral Heterogeneity in Human Ovarian Cancer","volume":"307","author":"Choi","year":"2011","journal-title":"Cancer Lett."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"14295","DOI":"10.1073\/pnas.97.26.14295","article-title":"Explaining the High Mutation Rates of Cancer Cells to Drug and Multidrug Resistance by Chromosome Reassortments That Are Catalyzed by Aneuploidy","volume":"97","author":"Duesberg","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1038\/onc.2010.245","article-title":"Genomic Analysis of Genetic Heterogeneity and Evolution in High-Grade Serous Ovarian Carcinoma","volume":"29","author":"Cooke","year":"2010","journal-title":"Oncogene"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Damia, G., and Broggini, M. (2019). Platinum Resistance in Ovarian Cancer: Role of DNA Repair. Cancers, 11.","DOI":"10.3390\/cancers11010119"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s00018-022-04395-y","article-title":"Preclinical Models of Epithelial Ovarian Cancer: Practical Considerations and Challenges for a Meaningful Application","volume":"79","author":"Ciucci","year":"2022","journal-title":"Cell Mol. Life Sci."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Psilopatis, I., Sykaras, A.G., Mandrakis, G., Vrettou, K., and Theocharis, S. (2022). Patient-Derived Organoids: The Beginning of a New Era in Ovarian Cancer Disease Modeling and Drug Sensitivity Testing. Biomedicines, 11.","DOI":"10.3390\/biomedicines11010001"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/s41591-019-0422-6","article-title":"An Organoid Platform for Ovarian Cancer Captures Intra- and Interpatient Heterogeneity","volume":"25","author":"Kopper","year":"2019","journal-title":"Nat. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-18-0474","article-title":"Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids","volume":"8","author":"Hill","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Spagnol, G., Sensi, F., De Tommasi, O., Marchetti, M., Bonaldo, G., Xhindoli, L., Noventa, M., Agostini, M., Tozzi, R., and Saccardi, C. (2023). Patient Derived Organoids (PDOs), Extracellular Matrix (ECM), Tumor Microenvironment (TME) and Drug Screening: State of the Art and Clinical Implications of Ovarian Cancer Organoids in the Era of Precision Medicine. Cancers, 15.","DOI":"10.3390\/cancers15072059"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.ygyno.2020.03.026","article-title":"Short-Term Organoid Culture for Drug Sensitivity Testing of High-Grade Serous Carcinoma","volume":"157","author":"Chen","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1002\/ijc.21599","article-title":"Molecular Profiling of Platinum Resistant Ovarian Cancer","volume":"118","author":"Helleman","year":"2006","journal-title":"Int. J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1023\/A:1013156407224","article-title":"Mechanisms Associated with Cell Adhesion Mediated Drug Resistance (CAM-DR) in Hematopoietic Malignancies","volume":"20","author":"Hazlehurst","year":"2001","journal-title":"Cancer Metastasis Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1002\/ijc.32854","article-title":"Ovarian Cancer-Associated Mesothelial Cells Induce Acquired Platinum-Resistance in Peritoneal Metastasis via the FN1\/Akt Signaling Pathway","volume":"146","author":"Yoshihara","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"7104","DOI":"10.1038\/s41598-017-07005-1","article-title":"Common Biological Phenotypes Characterize the Acquisition of Platinum-Resistance in Epithelial Ovarian Cancer Cells","volume":"7","author":"Sonego","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41419-020-2327-1","article-title":"ID1 Confers Cancer Cell Chemoresistance through STAT3\/ATF6-Mediated Induction of Autophagy","volume":"11","author":"Meng","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1111\/jcmm.14286","article-title":"Role of Jagged1\/STAT3 Signalling in Platinum-Resistant Ovarian Cancer","volume":"23","author":"Yang","year":"2019","journal-title":"J. Cell Mol. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1002\/jcb.30126","article-title":"Leukemia Associated RUNX1T1 Gene Reduced Proliferation and Invasiveness of Glioblastoma Cells","volume":"122","author":"Kumar","year":"2021","journal-title":"J. Cell Biochem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"215971","DOI":"10.1016\/j.canlet.2022.215971","article-title":"METTL3-Mediated N6-Methyladenosine Modification and HDAC5\/YY1 Promote IFFO1 Downregulation in Tumor Development and Chemo-Resistance","volume":"553","author":"Zhang","year":"2023","journal-title":"Cancer Lett."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3892\/or.2022.8293","article-title":"Molecular Mechanisms of Platinum-based Chemotherapy Resistance in Ovarian Cancer (Review)","volume":"47","author":"Yang","year":"2022","journal-title":"Oncol. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e65234","DOI":"10.7554\/eLife.65234","article-title":"A Non-Genetic, Cell Cycle-Dependent Mechanism of Platinum Resistance in Lung Adenocarcinoma","volume":"10","author":"Marzec","year":"2021","journal-title":"eLife"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Casas-Arozamena, C., Cortegoso, A., Pi\u00f1eiro-Perez, R., Abalo, A., Arias, E., Sampayo, V., Vilar, A., Bouso, M., Diaz, E., and Moreno-Bueno, G. (2022). Improving the Management of Endometrial Cancer Patients through the Use of Liquid Biopsy Analyses: A Case Report. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23158539"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1158\/1078-0432.CCR-16-3083","article-title":"Clinically Relevant Concentrations of Anticancer Drugs: A Guide for Nonclinical Studies","volume":"23","author":"Liston","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s43856-021-00019-x","article-title":"Patient-derived organoids reflect the genetic profile of endometrial tumors and predict patient prognosis","volume":"1","author":"Berg","year":"2021","journal-title":"Commun. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/17\/13208\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:38:59Z","timestamp":1760128739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/17\/13208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,25]]},"references-count":39,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["ijms241713208"],"URL":"https:\/\/doi.org\/10.3390\/ijms241713208","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,25]]}}}